Home › Compound Library › TUDCA (Tauroursodeoxycholic Acid)

TUDCA (Tauroursodeoxycholic Acid)

Longevityoral · inferred

Taurine-conjugated bile acid with cytoprotective properties beyond bile acid function. Inhibits ER stress (UPR modulation), prevents mitochondrial-mediated apoptosis (blocks BAX translocation), and is neuroprotective. FDA-approved in the EU as Taurolite for cholestatic liver disease. Popular supplement for liver support during oral anabolic steroid cycles. Also studied for ALS, Parkinson's, and retinal degeneration. Well-absorbed orally; undergoes enterohepatic circulation.

Projected serum levels — 500 mg, once daily

TUDCA (Tauroursodeoxycholic Acid)
TUDCA (Tauroursodeoxycholic Acid) modeled serum levels, 500 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 500 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 72.2 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 500 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Longevity
Route modeled
Oral
Model confidence
inferred
Half-life
3.5 h
Common dose
500 mg
Suggested maximum
1.5k mg/day
Reference dose range
250–1.5k mg (single dose)
Suggested cadence
once daily

Documented interactions

  • watch
    Glutathione (Injectable) + TUDCA (Tauroursodeoxycholic Acid) Stacked effects

    Glutathione (Injectable) and TUDCA (Tauroursodeoxycholic Acid) both push the endogenous glutathione pool in the same direction.

  • watch
    Milk Thistle (Silymarin / Silybin) + TUDCA (Tauroursodeoxycholic Acid) Stacked effects

    Milk Thistle (Silymarin / Silybin) and TUDCA (Tauroursodeoxycholic Acid) both push the endogenous glutathione pool in the same direction.

  • watch
    N-Acetyl Cysteine (NAC) + TUDCA (Tauroursodeoxycholic Acid) Stacked effects

    N-Acetyl Cysteine (NAC) and TUDCA (Tauroursodeoxycholic Acid) both push the endogenous glutathione pool in the same direction.

  • watch
    PQQ (Pyrroloquinoline Quinone) + TUDCA (Tauroursodeoxycholic Acid) Stacked effects

    PQQ (Pyrroloquinoline Quinone) and TUDCA (Tauroursodeoxycholic Acid) both push the endogenous glutathione pool in the same direction.

Serum checks 4 modeled interaction pairings for tudca (tauroursodeoxycholic acid) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Tauroursodeoxycholic acid (TUDCA) for amyotrophic lateral sclerosis: a phase II randomized, double-blind, placebo-controlled trial Elia AE et al. · European Journal of Neurology, 2016 DOI

    Phase II RCT (34 ALS patients) finding TUDCA 1g/day for 54 weeks slowed ALSFRS-R decline by 15% versus placebo, suggesting neuroprotective benefit via ER stress inhibition and anti-apoptotic mechanisms.

  2. Ursodeoxycholic acid and tauroursodeoxycholic acid for the treatment of liver diseases: a review Lazaridis KN et al. · Journal of Hepatology, 2001 DOI

    Comprehensive review establishing TUDCA's hepatoprotective mechanisms including membrane stabilization, reduction of hydrophobic bile acid toxicity, anti-apoptotic properties, and immunomodulatory effects.

  3. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A · European journal of neurology, 2016 DOI

    This citation reports a human clinical study involving TUDCA (Tauroursodeoxycholic Acid). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.